View in EDS

Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial.

Saved in:
Bibliographic Details
Title: Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial.
Authors: Powles T; Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, London; Royal Free National Health Service Trust, London, UK. Electronic address: thomas.powles1@nhs.net., Burotto M; Bradford Hill Clinical Research Center, Santiago, Chile., Escudier B; Gustave Roussy, Villejuif, France., Apolo AB; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA., Bourlon MT; Urologic Oncology Clinic, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico., Shah AY; MD Anderson Cancer Center, Houston, USA., Suárez C; Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Porta C; Department of Internal Medicine, University of Pavia, Pavia, Italy., Barrios CH; Centro de Pesquisa em Oncologia, Hospital São Lucas, PUCRS, Latin American Cooperative Oncology Group, Porto Alegre, Brazil., Richardet M; Fundación Richardet Longo, Instituto Oncológico de Córdoba, Córdoba, Argentina., Gurney H; Westmead Hospital and Macquarie University, Westmead and Sydney, Australia., Kessler ER; Division of Medical Oncology, Department of Internal Medicine, University of Colorado School of Medicine, Aurora, USA., Tomita Y; Departments of Urology and Molecular Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan., Bedke J; Department of Urology, Eberhard Karls University Tübingen, Tübingen, Germany., George S; Roswell Park Comprehensive Cancer Center, Buffalo., Scheffold C; Exelixis, Inc., Alameda., Wang P; Bristol Myers Squibb, Princeton., Fedorov V; Bristol Myers Squibb, Princeton., Motzer RJ; Memorial Sloan Kettering Cancer Center, New York., Choueiri TK; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston; Brigham and Women's Hospital, Harvard Medical School, Boston, USA.
Source: ESMO open [ESMO Open] 2024 May; Vol. 9 (5), pp. 102994. Date of Electronic Publication: 2024 Apr 20.
Publication Type: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38642472
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Powles+T%22">Powles T</searchLink>; Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, London; Royal Free National Health Service Trust, London, UK. Electronic address: thomas.powles1@nhs.net.<br /><searchLink fieldCode="AU" term="%22Burotto+M%22">Burotto M</searchLink>; Bradford Hill Clinical Research Center, Santiago, Chile.<br /><searchLink fieldCode="AU" term="%22Escudier+B%22">Escudier B</searchLink>; Gustave Roussy, Villejuif, France.<br /><searchLink fieldCode="AU" term="%22Apolo+AB%22">Apolo AB</searchLink>; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA.<br /><searchLink fieldCode="AU" term="%22Bourlon+MT%22">Bourlon MT</searchLink>; Urologic Oncology Clinic, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.<br /><searchLink fieldCode="AU" term="%22Shah+AY%22">Shah AY</searchLink>; MD Anderson Cancer Center, Houston, USA.<br /><searchLink fieldCode="AU" term="%22Suárez+C%22">Suárez C</searchLink>; Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Porta+C%22">Porta C</searchLink>; Department of Internal Medicine, University of Pavia, Pavia, Italy.<br /><searchLink fieldCode="AU" term="%22Barrios+CH%22">Barrios CH</searchLink>; Centro de Pesquisa em Oncologia, Hospital São Lucas, PUCRS, Latin American Cooperative Oncology Group, Porto Alegre, Brazil.<br /><searchLink fieldCode="AU" term="%22Richardet+M%22">Richardet M</searchLink>; Fundación Richardet Longo, Instituto Oncológico de Córdoba, Córdoba, Argentina.<br /><searchLink fieldCode="AU" term="%22Gurney+H%22">Gurney H</searchLink>; Westmead Hospital and Macquarie University, Westmead and Sydney, Australia.<br /><searchLink fieldCode="AU" term="%22Kessler+ER%22">Kessler ER</searchLink>; Division of Medical Oncology, Department of Internal Medicine, University of Colorado School of Medicine, Aurora, USA.<br /><searchLink fieldCode="AU" term="%22Tomita+Y%22">Tomita Y</searchLink>; Departments of Urology and Molecular Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.<br /><searchLink fieldCode="AU" term="%22Bedke+J%22">Bedke J</searchLink>; Department of Urology, Eberhard Karls University Tübingen, Tübingen, Germany.<br /><searchLink fieldCode="AU" term="%22George+S%22">George S</searchLink>; Roswell Park Comprehensive Cancer Center, Buffalo.<br /><searchLink fieldCode="AU" term="%22Scheffold+C%22">Scheffold C</searchLink>; Exelixis, Inc., Alameda.<br /><searchLink fieldCode="AU" term="%22Wang+P%22">Wang P</searchLink>; Bristol Myers Squibb, Princeton.<br /><searchLink fieldCode="AU" term="%22Fedorov+V%22">Fedorov V</searchLink>; Bristol Myers Squibb, Princeton.<br /><searchLink fieldCode="AU" term="%22Motzer+RJ%22">Motzer RJ</searchLink>; Memorial Sloan Kettering Cancer Center, New York.<br /><searchLink fieldCode="AU" term="%22Choueiri+TK%22">Choueiri TK</searchLink>; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston; Brigham and Women's Hospital, Harvard Medical School, Boston, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101690685%22">ESMO open</searchLink> [ESMO Open] 2024 May; Vol. 9 (5), pp. 102994. <i>Date of Electronic Publication: </i>2024 Apr 20.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101690685 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2059-7029 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220597029%22">20597029 </searchLink><i>NLM ISO Abbreviation: </i>ESMO Open <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38642472
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.esmoop.2024.102994
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 102994
    Titles:
      – TitleFull: Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Powles T
      – PersonEntity:
          Name:
            NameFull: Burotto M
      – PersonEntity:
          Name:
            NameFull: Escudier B
      – PersonEntity:
          Name:
            NameFull: Apolo AB
      – PersonEntity:
          Name:
            NameFull: Bourlon MT
      – PersonEntity:
          Name:
            NameFull: Shah AY
      – PersonEntity:
          Name:
            NameFull: Suárez C
      – PersonEntity:
          Name:
            NameFull: Porta C
      – PersonEntity:
          Name:
            NameFull: Barrios CH
      – PersonEntity:
          Name:
            NameFull: Richardet M
      – PersonEntity:
          Name:
            NameFull: Gurney H
      – PersonEntity:
          Name:
            NameFull: Kessler ER
      – PersonEntity:
          Name:
            NameFull: Tomita Y
      – PersonEntity:
          Name:
            NameFull: Bedke J
      – PersonEntity:
          Name:
            NameFull: George S
      – PersonEntity:
          Name:
            NameFull: Scheffold C
      – PersonEntity:
          Name:
            NameFull: Wang P
      – PersonEntity:
          Name:
            NameFull: Fedorov V
      – PersonEntity:
          Name:
            NameFull: Motzer RJ
      – PersonEntity:
          Name:
            NameFull: Choueiri TK
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: 2024 May
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 2059-7029
          Numbering:
            – Type: volume
              Value: 9
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: ESMO open
              Type: main
ResultId 1